only considered individuals with VFs above 25% without further assessment of the penetrance after gene panel testing, whereas another study group chose a VF of 35% as a cutoff for the analysis of penetrance of prostate cancer in male carriers of a pathogenic TP53 variant.38 The gene discussed is TP53; the disease is prostate cancer.